NEW YORK (GenomeWeb) — Singapore-based Lucence Diagnostics and NovogeneAIT Genomics Singapore announced today that they have partnered to develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.
According to the partners, the tests will be designed to analyze the genetics of cancer tissue to help personalize a patient's treatment regimen and will focus on cancers prevalent in Asia. Additional terms of the deal were not disclosed.